Navigation Links
Surface Logix Commences Phase 2a Clinical Trial of SLx-2101 in Raynaud's Disease

BOSTON, -- Surface Logix Inc. today announced the initiation of a Phase 2a clinical trial for SLx-2101 in patients with secondary Raynaud's disease. SLx-2101 is a novel , long-acting PDE-5 inhibitor being developed for the management of diseases associated with vascular dysfunction such as Raynaud's, a vasospastic disorder of small blood vessels leading to a marked reduction of blood flow to areas such as the fingers and toes. Often triggered by exposure to cold, Raynaud's is associated with painful blue or white digits, and in severe cases, may lead to the development of digital ulcers.

"PDE-5 inhibition holds promise in several cardiovascular indications, though many disorders such as Raynaud's are currently not addressed by marketed PDE-5 inhibitors," commented Paul Sweetnam, Ph.D., Chief Scientific Officer of Surface Logix. "We used our novel chemistry platform to design SLx-2101 to have a profile that would deliver fast onset and long duration of therapeutic effects in difficult-to-treat conditions such as Raynaud's, potentially enabling quicker, longer-lasting relief to patients."

"The initiation of this trial is part of Surface Logix's multiple indication development plan for SLx-2101. We believe that it has applicability in cardiovascular indications beyond erectile dysfunction and are therefore pursuing its advancement in specialized indications, such as Raynaud's, as well as in larger cardiovascular markets," said Jim Mahoney, President and Chief Executive Officer of Surface Logix.

The Phase 2a trial is a single European center, randomized, double-blind, placebo-controlled, crossover pilot study that will enroll 20 patients with secondary Raynaud's disease. The trial is designed to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days. The primary objective of this trial is to investigate the severity of secondary Raynaud's disease-related attacks during the dosing period. Secondary objectives include evaluating the frequency and total daily duration of disease-related attacks during the dosing period, the safety and tolerability of SLx-2101, and the effect of the drug on capillary blood flow velocity and vasospastic symptoms.

Surface Logix also initiated a Phase 2a clinical trial to test the safety, tolerability and pharmacodynamics of orally administered SLx-2101 in patients with hypertension in June 2007. Interim data from a Phase 2a study of SLx-2101 in erectile function confirmed its activity 48 hours after a single dose of 10mg, making it the first PDE-5 inhibitor to confirm such prolonged duration of activity using an objective measure.

Phase 1 studies of SLx-2101 in healthy male volunteers demonstrated its favorable safety, tolerability, pharmacokinetics and pharmacodynamic activity. Additionally, in preclinical animal models, the candidate was highly potent and selective, induced rapid cellular and tissue response and provided an extended duration of action.


'"/>




Related medicine news :

1. Lunar Forces Affect The Surface Of The Earth
2. Controversy Over The Fee Structure In Private Medical Colleges Surfaces Yet Again
3. Meningitis C Surfaces in Toronto:Public Alerted
4. New Study Links Western Wildfires to Atlantic Ocean Surface Temperatures
5. Copper Alloys Surfaces Touted As Pathogen Killers
6. Flesh-eating Bugs Surface in Singapore
7. InfoLogix, Inc. the Leading Healthcare Technology Company SaysHealthcare Informatics
8. Pfizer Commences Its Advertising for Celebrex with All the Warnings
9. Natco Pharma Commences Production At Dehradun Unit
10. Chinas First Gay Health Clinic Commences Operations
11. Mental Health - NHS Trust Commences Specialist Transition Service
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... , ... March 29, 2017 , ... ... many scientific laboratories. The assembly protocols involve many repetitive steps and often scientists ... automation, which enables the high-throughput needed, and results in a lower error rate ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (SOGO™), a specialized continuing medical education conference for clinicians who manage some of ... Square, New York. , The program will be led by co- chairs ...
(Date:3/28/2017)... ... March 28, 2017 , ... A recent ... improve teacher quality, the field must first improve teacher preparation program design. It ... the next” and that decades of input- and outcome-based research has failed to ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Ruel Williamson brings his extensive knowledge of appraisals, property values, ad valorem taxation, ... real estate valuation industry for more than 40 years. , “Ruel is a ...
(Date:3/28/2017)... , ... March 29, 2017 , ... Dr. Isabella Wentz, ... launching a 9-part video series titled The Thyroid Secret. Dr. Wentz talked about journey ... which emphasizes the fact that medication IS NOT the only solution to deal with ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... The global emerging cancer diagnostics market is expected to ... 2023 and reach a figure of $6.34 billion by ... disease and is affecting a huge population. Many technologies ... is focused on emerging cancer diagnostics market specifically on ... to factors such as: increasing number of cancer cases, ...
(Date:3/28/2017)... LAS VEGAS , March 28, 2017  Las ... first surgeries with XEN45 Gel Stent (Allergan, ... built up in the eye, thereby reducing intraocular pressure ... 60 million people globally are affected by glaucoma that ... in vision loss and blindness, if left untreated. ...
(Date:3/28/2017)... , March 28, 2017 The ... (dupilumab) injection to treat adults with moderate-to-severe eczema ... eczema is not controlled adequately by topical therapies, ... advisable. Dupixent can be used with or without ... demonstrates our commitment to approving new and innovative ...
Breaking Medicine Technology: